3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Lenalidomide
11
Dexamethasone
11
fludarabine
9
Cyclophosphamide
7
Bortezomib
6
fludarabine phosphate
5
Melphalan
5
pomalidomide
4
isatuximab
3
daratumumab
3
Tacrolimus
3
Mycophenolic Acid
3
Busulfan
3
dacetuzumab
2
Whole-Body Irradiation
2
Thiotepa
2
Stem Cell Transplantation
2
Leukapheresis
2
KW-2478
2
Granulocyte Colony-Stimulating Factor
2
Cyclosporine
2
Calcium Dobesilate
2
tanespimycin
1
spartalizumab
1
sargramostim
1
ricolinostat
1
pirtobrutinib
1
pembrolizumab
1
nirogacestat
1
ixazomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
ficlatuzumab
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled